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LETTERS TO THE EDITORRegarding “Withdrawal of article by the FDA after
objection from Medtronic”
As one of the authors of the paper “Aneurysm-related mortal-
ity rates in the US AneuRx clinical trial,” which was accepted for
publication and then withdrawn by the FDA under threat of legal
action from Medtronic, I write to respond to the issues raised by
the Cronenwett and Seeger editorial (J Vasc Surg 2004;40:209-
10). In a letter to the FDA, Medtronic claimed that the outcomes
data used were “proprietary information” protected as confiden-
tial. In fact, the data were used in the FDA’s AneuRx Public Health
Notice dated December 17, 2003, making the information public,
and the manuscript had been cleared by the FDA’s Freedom of
Information Office as containing neither proprietary nor protected
health information. Medtronic was also concerned that we had
used the predicted mortality rate of 1% to 2% from open repair to
show that the cumulative aneurysm-related death rate following
use of the AneuRx graft would exceed that of open repair after the
second year of follow-up. In fact, the evidence supports this
conclusion, showing that the rate of mortality in the AneuRx
patients does not decline with time. Previous published studies
justify using the 2% open mortality rate for high-volume institu-
tions for comparison, especially since the AneuRx cohort excluded
patients with serious comorbidities such as renal failure, obesity,
ASA above level IV, and aortoiliac occlusive disease. The question
of whether the mortality rate in AneuRx patients actually increases
with time is a valid concern since the trend in the data was not
statistically significant. This could be answered by additional data
held by the company since the information submitted to the FDA
did not go beyond October, 2002.
Of most concern is the response of FDA administration, which
failed to support its own investigators after evidence that there was
no merit in the company’s complaints. This study belongs in the
leading vascular journal so that it can be debated nationally and
internationally. Just as patients still die from pulmonary embolism
after placement of a Greenfield filter, patients are dying from aneu-
rysm rupture after placement of stent grafts. It does not mean that
either technology is inappropriate treatment. Instead, users of these
medical devices and their patients should be fully informed of their
associated risks. Inability to publish this manuscript will have a chilling
effect on further critical investigation at the FDA, and could under-
mine the confidence of physicians and the public in its objectivity.
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Inappropriate industry influence on FDA processes
The recent withdrawal by the FDA of a peer-reviewed manu-
script concerning the AneuRx stent graft as a result of legal
pressure from industry is an alarming episode that should trouble
all health care providers as well as the public at large. As reported in
the 9 July 2004 Wall Street Journal, the FDA made this request
under direct threat of litigation by Medtronic after the accepted
article, which included publicly available information, had initially
appeared on the Journal of Vascular Surgery Web site. The mission
statement of the FDA notes that it performs “. . .high quality,
science-based work that results in maximizing consumer protec-
tion.” For the past 15 years, I have voluntarily served as a consul-
tant to the Circulatory Devices Panel of the FDA and have had the
privilege of working with many FDA employees who are incredibly
dedicated, hard-working public servants of unquestioned ethics,594who strive to carry out that mission every day of their professional
lives. I continue to have nothing but the utmost respect for their
service. My concern is with the political leadership of the FDA. It
is unacceptable that this mission should be compromised by extra-
neous pressure to impede the dissemination of information. What
is particularly disconcerting is that the episode depicted in the Wall
Street Journal article is strikingly similar to an experience I have had
recently with the FDA.
I had been invited to participate in the FDA Circulatory
Devices carotid stent panel meeting in April 2004 concerning the
SAPPHIRE carotid stent trial data. I felt well qualified to partici-
pate in this deliberation in light of my long-standing interest in
carotid artery disease. Although I believe that carotid endarterec-
tomy is the best treatment for the majority of patients with carotid
disease, I believe carotid stenting is appropriate for truly high-risk
patients and have recommended this in my practice. My public
position on these issues, including the SAPPHIRE trial, was well
known to the leadership of the Circulatory Devices panel prior to
my inclusion on the carotid stent panel. Over the last 15 years of
service that I have provided to the FDA, there never has been a
question of my commitment to a fair, ethical, and unbiased assess-
ment of the data presented to our panel meetings. However,
somewhat inexplicably, just a few weeks prior to the carotid stent
panel meeting, I was called by the leadership of the Circulatory
Devices section and informed that I was being dropped from the
panel because of my public commentary concerning carotid stent-
ing. After I wrote a strongly worded letter of protest, and empha-
sized that my public statements on the issue were well known to
the FDA prior to my selection for the panel, I was explicitly told by
an individual at the highest level of leadership in the Devices
Section that “if I were allowed to participate, and if the carotid
stent device under consideration were not approved, the FDA
would be sued by the industry sponsor.” It was clear that I had
been eliminated on the basis of pressure from industry, in this case
Cordis, Inc. I was, needless to say, dumbfounded, but in light of the
recent AneuRx manuscript withdrawal, perhaps I should not have
been. The FDA had apparently reacted on the basis of a fear of
litigation, as subsequently was the case with the AneuRx article. It
appeared to me that the FDA leadership had caved to pressure from
those it was supposed to regulate, and this is absolutely unacceptable.
While FDA personnel have always and must continue to work
closely with industry in the design and evaluation of device trials, it
appears that the leadership of the FDA has recently yielded exces-
sive control of that regulatory process to the industry that it is
supposed to regulate, and this is wrong. Suppression of the publi-
cation of trial data, positive or negative; preventing the communi-
cation of information that consumers and health care providers
need to make informed judgments; and undue control, including
veto power, over who can most effectively support the regulatory
function of our government in assessing medical device and phar-
maceutical scientific studies is intolerable, and will ultimately be
detrimental to all stakeholders in the system, and most importantly
our patients. The public interest should be our moral compass.
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Misperceptions regarding the long-term safety of the
AneuRx stent graft
On July 9, 2004, the Wall Street Journal reported that an
article posted on the Journal of Vascular Surgery Web site was
